These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12783575)

  • 1. The coagulation system as a target for experimental therapy of human gliomas.
    Loynes JT; Zacharski LR
    Expert Opin Ther Targets; 2003 Jun; 7(3):399-404. PubMed ID: 12783575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins and blood coagulation.
    Undas A; Brummel-Ziedins KE; Mann KG
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):287-94. PubMed ID: 15569822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The coagulation system as a target for the treatment of human gliomas.
    Ornstein DL; Meehan KR; Zacharski LR
    Semin Thromb Hemost; 2002 Feb; 28(1):19-28. PubMed ID: 11885022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of anticoagulants on cancer: heparins.
    Pineo GF; Hull RD
    Cancer Treat Res; 2009; 148():259-75. PubMed ID: 19377929
    [No Abstract]   [Full Text] [Related]  

  • 6. Anticoagulant therapy: basic principles, classic approaches and recent developments.
    Sinauridze EI; Panteleev MA; Ataullakhanov FI
    Blood Coagul Fibrinolysis; 2012 Sep; 23(6):482-93. PubMed ID: 22732252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostasis and malignancy.
    Francis JL; Biggerstaff J; Amirkhosravi A
    Semin Thromb Hemost; 1998; 24(2):93-109. PubMed ID: 9579631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ProCGlobal and endogenous thrombin potential during pregnancy.
    Hron G; Kyrle PA; Kaider A; Philipp K; Pabinger I; Kollars M; Eichinger S
    Am J Obstet Gynecol; 2010 Nov; 203(5):463.e1-6. PubMed ID: 20598285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of low molecular weight heparin in pregnancy.
    Shiach CR
    Hematology; 2003 Feb; 8(1):47-52. PubMed ID: 12623427
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties.
    Stassen JM; Lambeir AM; Matthyssens G; Ripka WC; Nyström A; Sixma JJ; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):646-54. PubMed ID: 8585001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation and metastasis: what does the experimental literature tell us?
    Gil-Bernabé AM; Lucotti S; Muschel RJ
    Br J Haematol; 2013 Aug; 162(4):433-41. PubMed ID: 23691951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation: the present and future.
    Van Aken H; Bode C; Darius H; Diehm C; Encke A; Gulba DC; Haas S; Hacke W; Puhl W; Quante M; Riess H; Scharf R; Schellong S; Schrör T; Schulte KL; Tebbe U
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):195-204. PubMed ID: 11441979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
    Dietrich W
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.